Last reviewed · How we verify
Standard neoadjuvant therapy
Standard neoadjuvant therapy involves administering a combination of chemotherapy drugs before surgery to reduce tumor size and improve surgical outcomes.
Standard neoadjuvant therapy involves administering a combination of chemotherapy drugs before surgery to reduce tumor size and improve surgical outcomes. Used for Breast cancer, stage II or III, Colorectal cancer, stage II or III.
At a glance
| Generic name | Standard neoadjuvant therapy |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach allows for more effective removal of cancerous tissue and can lead to improved survival rates. The specific chemotherapy agents used may vary depending on the type and stage of cancer being treated.
Approved indications
- Breast cancer, stage II or III
- Colorectal cancer, stage II or III
Common side effects
- Nausea
- Fatigue
- Hair loss
- Neutropenia
- Anemia
Key clinical trials
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (PHASE2)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC (PHASE2)
- A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (PHASE2, PHASE3)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Prospective Validation of Ataraxis AI Test for Predicting Treatment Response in Neoadjuvant Breast Cancer
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard neoadjuvant therapy CI brief — competitive landscape report
- Standard neoadjuvant therapy updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI